21st Jul 2015 07:56
LONDON (Alliance News) - Clinigen Group PLC Tuesday said its collaboration with Pharming Group NV to provide access to Pharming's RUCONEST programme is now live.
The pharmaceutical company said that RUCONEST is a recombinant human C1-inhibitor for the treatment of acute attacks of hereditary angioedema. The access programme, which was initiated by HAEi, the international patient organisation for C1-inhibitor deficiencies, enables patients in all countries where RUCONEST is not commercially available to gain access to the drug through an ethical and regulatory-compliant mechanism.
"We are very pleased to work with Pharming to help HAEi realise their mission to ensure that sufferers of hereditary angioedema worldwide can access this effective and potentially life-saving treatment. The ground-breaking programme provides RUCONEST to patients in an ethical and compliant way, removing the need and the risk for patients to resort to other less reliable or even illegal sources of the drug," Simon Estcourt, managing director of Managed Access at Clinigen Group said.
Shares in Clinigen Group were trading up 0.5% at 668.50 pence early Tuesday.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L